Should all diabetic patients receive statins?

Current Atherosclerosis Reports

Volumn 8, Issue 1, 2006, Pages 13-18

  Garcia, Paul J ^a   Spellman, Craig W ^b  

^a University of North Texas Health Science Center   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ATORVASTATIN; CHOLESTEROL; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; METFORMIN; NICOTINIC ACID; PLACEBO; SIMVASTATIN;

BLOOD PRESSURE REGULATION; BLOOD VESSEL INJURY; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DIABETES CONTROL; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DRUG EFFICACY; DRUG SAFETY; GLUCOSE BLOOD LEVEL; HUMAN; INFLAMMATION; INSULIN RESISTANCE; LIVER TOXICITY; METABOLIC SYNDROME X; MYOPATHY; PATIENT CARE; PREVALENCE; REVIEW; RHABDOMYOLYSIS; RISK REDUCTION; VASCULAR DISEASE;

ATHEROSCLEROSIS; CLINICAL TRIALS; DIABETES COMPLICATIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;

EID: 33646422734     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-006-0059-z     Document Type: Review

References (61)

1. International Diabetes Federation Task Force on Diabetes Health Economics: Facts, Figures and Forecasts. Brussels, Belgium: International Diabetes Federation; 1997.
2. Boyle JP, Honeycutt AA, Narayan KM, et al.: Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the U.S. Diabetes Care 2001, 24:1936-1940.
3. Lundberg V, Stegmayr B, Asplund K, et al.: Diabetes as a risk factor for myocardial infarction: population and gender perspectives. J Intern Med 1997, 241:485-492.
4. Lotufo PA, Gaziano JM, Chae CU, et al.: Diabetes and all-cause and coronary heart disease mortality among US male physicians. Arch Intern Med 2001, 161:242-247.
5. Liao Y, Cooper RS, Ghali JK, et al.: Sex differences in the impact of coexistent diabetes on survival in patients with coronary heart disease. Diabetes Care 1993, 16:708-713.
6. Hu FB, Stampfer MJ, Solomon CG, et al.: The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow-up. Arch Intern Med 2001, 161:1717-1723.
7. Kannel WB, McGee DL: Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study. Diabetes Care 1979, 2:120-126.
8. Haffner SM, Lehto S, Ronnemaa T, et al.: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998, 339:229-234.
9. Wilson PW, Kannel WB: Epidemiology of hyperglycemia and atherosclerosis. In Hyperglycemia, Diabetes and Vascular Disease. New York: Oxford University Press; 1992:21-29.
10. Natarajan S, Liao Y, Cao G, et al.: Sex differences in risk for coronary heart disease mortality associated with diabetes and established heart disease. Arch Intern Med 2003, 163:1735-1740.
11. Saaddine JB, Engelgau MM, Beckles GL, et al.: A diabetes report card for the United States: quality of care in the 1990s. Ann Intern Med 2002, 136:565-574.
12. Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002, 287:356-359.
13. Kahn R, Buse J, Ferrannini E, et al.: The metabolic syndrome: time for a critical appraisal. Diabetes Care 2005, 28:2289-2304.
14. Isomaa B, Almgren P, Tuomi T, et al.: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001, 24:683-689.
15. Ross R: Atherosclerosis - an inflammatory disease. N Engl J Med 1999, 340:115-126.
16. Cayatte AJ, Palacino JJ, Horten K, et al.: Chronic inhibition of nitric oxide production accelerates neointimal formation and impairs endothelial function in hypercholesterolemic rabbits. Arterioscler Thromb 1994, 14:753-759.
17. Hamon M, Vallet B, Bauters C, et al.: Long-term oral administration of L-arginine reduces intimal thickening and enhances neoendothelium-dependent acetylcholine-induced relaxation after arterial injury. Circulation 1994, 90:1357-1362.
18. Liao JK, Bettmann MA, Sandor T, et al.: Differential impairment of vasodilator responsiveness of peripheral resistance and conduit vessels in humans with atherosclerosis. Circ Res 1991, 68:1027-1034.
19. Radomski MW, Palmer RM, Moncada S: An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci U S A 1990, 87:5193-5197.
20. Garg UC, Hassid A: Nitric oxide-generating vasodilators and 8-bromocyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989, 83:1774-1777.
21. Kubes P, Suzuki M, Granger DN: Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA 1991, 88:4651-4655.
22. Creager M, Luscher T, Cosentino F, et al.: Diabetes and vascular disease: pathophysiology, clinical consequences and medical therapy: part 1. Circulation 2003, 108:1527-1532.
23. Boden G: Free fatty acids, insulin resistance in the pathogenesis of type 2 diabetes mellitus. Proc Assoc Am Physicians 1999, 111:241-248.
24. Laakso M, Edelman SV, Brechtel G, et al.: Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man: a novel mechanism for insulin resistance. J Clin Invest 1990, 85:1844-1852.
25. Mather KJ, Verma S, Anderson TJ: Improved endothelial function with metformin in type 2 diabetes mellitus. J Am Coll Cardiol 2001, 37:1344-1350.
26. Watanabe Y, Sunayama S, Shimada K, et al.: Troglitazone improves endothelial dysfunction in patients with insulin resistance. J Atheroscler Thromb 2000, 7:159-163.
27. Vaughan CJ, Murphy MB, Buckley BM: Statins do more than just lower cholesterol. Lancet 1996, 348:1079-1082.
28. Harris MB, Blackstone MA, Sood SG, et al.: Acute activation and phosphorylation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors. Am J Physiol Heart Circ Physical 2004, 287:H560-H566.
29. Feron O, Dessy C, Deesager JP, et al.: Hydroxy-methyl-glutaryl-coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation 2001, 103:113-118.
30. Ohara Y, Peterson TE, Harrison DG: Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest 1993, 91:2546-2551.
31. Bellosta S, Ferri N, Bernini F, et al.: Non-lipid related effects of statins. Ann Med 2000, 32:164-176.
32. Fukumoto H, Naito Z, Asano G, et al.: Immunohistochemical and morphometric evaluations of coronary atherosclerotic plaques associated with myocardial infarctions and diabetes mellitus. J Atheroscler Thromb 1998, 5:29-35.
33. Hussain MJ, Peakman M, Gallati H, et al.: Elevated levels of macrophage-derived cytokines precede and accompany the onset of IDDM. Diabetologia 1996, 39:60-69.
34. Vinik AI, Erbas T, Park TS, et al.: Platelet dysfunction in type 2 diabetes. Diabetes Care 2001, 24:1476-1485.
35. Assert R, Scherk G, Bumbure A, et al.: Regulation of protein kinase C by short term hyperglycemia in human platelets in vivo and in vitro. Diabetologia 2001, 44:188-195.
36. Li Y, Woo V, Bose R: Platelet hyperactivity and abnormal Ca(2+) homeostasis in diabetes mellitus. Am J Physiol Heart Circ Physiol 2001, 280:H1480-H1489.
37. Ceriello A, Giugliano D, Quatraro A, et al.: Evidence for a hyperglycaemia-dependent decrease of antithrombin III-thrombin complex formation in humans. Diabetologia 1990, 33:163-167.
38. Vaughan CJ, Gotto AM Jr, Basson CT: The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol 2000, 35:1-10.
39. Degraeve F, Bolla M, Blaire S, et al.: Modulation of COX-2 expression by statins in human aortic smooth muscle cells. Involvement of geranylgeranylated proteins. J Biol Chem 2001, 276:46849-46855.
40. Bourcier T, Libby P: HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells. Arterioscler Thromb Vasc Biol 2000, 20:556-562.
41. Cheung BM, Lauder IJ, Lau C, et al.: Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. Br J Clin Pharmacol 2004, 57:640-651.
42. Goraya TY, Leibson CL, Palumbo PJ, et al.: Coronary atherosclerosis in diabetes mellitus: a population-based autopsy study. J Am Coll Cardiol 2002, 40:946-953.
43. Wackers FJ, Young LH, Inzucchi K, et al.: Detection of silent myocardial ischemia in asymptomatic diabetic subjects. Diabetes Care 2004, 27:1954-1961.
44. Miettinen H, Lehto S, Salomaa V, et al.: Impact of diabetes on mortality after the first myocardial infarction. Diabetes Care 1998, 21:69-75.
45. Franklin K, Goldberg RJ, Spencer F, et al.: Implications of diabetes in patients with acute coronary syndromes: the global registry of acute coronary events. Arch Intern Med 2004, 164:1457-1463.
46. Heart Protection Study Collaborative Group: MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003, 361:2005-2016.
47. Colhoun HM, Betteridge DJ, Durrington PN, et al.: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study (CARDS): multicentre randomised-placebo-controlled trial. Lancet 2004, 364:685-696.
48. Rubins HB, Robins SJ, Collins D, et al.: Distribution of lipids in 8,500 men with coronary artery disease. Am J Cardiol 1995, 75:1196-1201.
49. Krop JS, Powe NR, Weller WE, et al.: Patterns of expenditures and use of services among older adults with diabetes: implications for the transition to capitated managed care. Diabetes Care 1998, 21:747-752.
50. Johannesson M, Jonsson B, Kjekshus J, et al.: Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. N Engl J Med 1997, 336:332-336.
51. Grover S, Alexander C, Coupal L, et al.: How cost-effective is the treatment of dyslipidemia in patients with diabetes but without cardiovascular disease? Diabetes Care 2001, 24:45-50.
52. Salmela PI, Sotaniemi EA, Niemi M, et al.: Liver function tests in diabetic patients. Diabetes Care 1984, 7:248-254.
53. Neuschwander-Tetri BA, Caldwell S: Nonalcoholic steatohepatitis: summary of AASLD single topic conference. Hepatology 2003, 37:1202-1219.
54. Angulo P: Nonalcoholic fatty liver disease. N Engl J Med 2002, 346:1221-1231.
55. Chalasani N, Aljadhey H, Kesterson J, et al.: Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 2004, 126:1287-1292.
56. Baig NA, Herrine SK, Rubin R: Liver disease and diabetes mellitus. Clin Lab Med 2001, 21:193-207.
57. Lebovitz H, Krieder M, Freed M: Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction. Diabetes Care 2002, 25:815-821.
58. LaRosa JC, Grundy SM, Waters DD, et al.: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Eng J Med 2005, 352:1425-1435.
59. Pasternak RC, Smith SC Jr, Bairey-Merz CN, et al.: ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Stroke 2002, 33:2337-2341.
60. Frick MH, Elo O, Haapa K, et al.: Helsinki heart study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987, 317:1237-1245.
61. Rubins HB, Robins SJ, Collins D, et al.: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999, 341:410-418.